Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 3 (2006), Issue 3 (March)

1. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
   Lancet Oncol, 7(3): 223-9. [Abstract] [Full-text]
2. Selenium binding protein 1 in ovarian cancer.
   Int J Cancer, 118(10): 2433-40. [Abstract] [Full-text]
3. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
   Int J Cancer, 118(10): 2636-8. [Abstract] [Full-text]
4. Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.
   Oncol Nurs Forum, 33(2): E27-35. [Abstract] [Full-text]
5. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.
   Br J Cancer, 94(5): 642-6. [Abstract] [Full-text]
6. Alcohol intake and ovarian cancer risk: a pooled analysis of 10 cohort studies.
   Br J Cancer, 94(5): 757-62. [Abstract] [Full-text]
7. Expression of Y-box-binding protein dbpC/contrin, a potentially new cancer/testis antigen.
   Br J Cancer, 94(5): 710-6. [Abstract] [Full-text]
8. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours.
   Br J Cancer, 94(5): 686-91. [Abstract] [Full-text]
9. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary.
   J Pathol, 208(5): 708-13. [Abstract] [Full-text]
10. Second and third malignant solid tumor in a girl with ovarian Sertoli-Leydig tumor.
    Pediatr Blood Cancer, 46(5): 654-6. [Abstract] [Full-text]
11. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase.
    Proc Natl Acad Sci U S A, 103(10): 3775-80. [Abstract] [Full-text]
12. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Proc Natl Acad Sci U S A, 103(10): 3770-4. [Abstract] [Full-text]
13. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.
    Proc Natl Acad Sci U S A, 103(10): 3914-9. [Abstract] [Full-text]
14. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models.
    Endocrinology, 147(4): 1761-9. [Abstract] [Full-text]
15. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
    J Clin Oncol, 24(9): 1454-8. [Abstract] [Full-text]
16. A distinct molecular profile associated with mucinous epithelial ovarian cancer.
    Br J Cancer, 94(6): 904-13. [Abstract] [Full-text]
17. Surveillance of women at high risk for hereditary ovarian cancer is inefficient.
    Br J Cancer, 94(6): 814-9. [Abstract] [Full-text]
18. Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines.
    Br J Cancer, 94(6): 914-21. [Abstract] [Full-text]
19. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.
    Carcinogenesis, 27(4): 729-39. [Abstract] [Full-text]
20. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.
    Biochem J, 395(2): 311-8. [Abstract] [Full-text]
21. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
    J Surg Oncol, 93(5): 379-86. [Abstract] [Full-text]
22. Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesis.
    J Mol Biol, 358(1): 310-29. [Abstract] [Full-text]

© 2004-2011 Ovarian Cancer Research Today. All Rights Reserved.